

BioMarin Patient and
Physician Support (BPPS)
for NAGLAZYME™ (galsulfase)

Please see Indication and
Important Safety Information
on back cover.



BPPS for NAGLAZYME™ (galsulfase)

BioMarin Patient and Physician Support (BPPS)


Beginning a unique treatment such as NAGLAZYME™ (galsulfase) can seem challenging at first. That's why BPPS is here to help. We'll help you through the entire process, step by step.

Through BPPS, BioMarin is committed to working with you, your family, your healthcare providers (physicians, nurses, and staff), and insurance companies to help make your treatment with NAGLAZYME as easy as possible.




Here for you

BPPS is a free, confidential service. Our staff is made up of patient advocates—people who care about you. At BPPS, we are a team of people who have experience in customer service, reimbursement, and insurance issues. We provide individualized support to you and your physician. At BPPS, our priority is to help you.



BPPS is a free, confidential service to help patients

Because NAGLAZYME treats a rare disease, health insurance policies and a coordinated treatment initiation plan may not be in place. Initially, it may take time to set up reimbursement and weekly infusions. That's why BPPS is here to work with you, your physician's office, your health insurance company, and your infusion center to coordinate the steps. BPPS may assist you in securing and maintaining insurance coverage, identifying treatment centers, setting up appointments, and answering reimbursement questions.




The first step is to complete the "Patient Authorization to Share Health Information for NAGLAZYME Treatment"

In order to coordinate the steps for obtaining coverage for NAGLAZYME, we will need to exchange personal information related to your treatment. The Patient Authorization to Share Health Information allows us to begin working for you and attempt to secure health insurance coverage and settle reimbursement matters.



BPPS for NAGLAZYME™ (galsulfase)

Your doctor's office may also be required to complete a form called the **"Statement of Medical Necessity,"** and provide additional information about your treatment plan.



Your BPPS case manager will help lead you through the final steps toward treatment with NAGLAZYME™ (galsulfase)

We will assign a BPPS case manager to provide step-by-step guidance for you through all aspects of your treatment plan.

Your BPPS case manager will help you navigate through the insurance process. We will determine the maximum health benefits available from your insurance carrier and inform you of what your co-pay/deductible amounts will be. If needed, BPPS may be able to help you find alternative insurance for your needs.


The BPPS case manager will work with your doctor to help locate sites in your area equipped to provide you with NAGLAZYME and handle the details needed to coordinate reimbursement. We will keep you and your doctor informed throughout the entire process, so that you have a single point of contact for your reimbursement concerns.



BPPS helps you every step of the way

Our mission is to help patients in receiving the treatment they need. We're here for you:

- To provide step-by-step guidance
- To coordinate reimbursement with your insurance company
- To help accommodate special needs related to your treatment
- To answer treatment questions you may have



If there is a delay in coverage, patient assistance programs may be able to help bridge the gap

BPPS works closely with patient assistance programs to help bridge the gap for qualified patients who may need financial assistance to begin or continue therapy.

BPPS for NAGLAZYME™ (galsulfase)



If your health plan or coverage should change for any reason, your BPPS case manager may assist you with the transition

If your coverage changes for any reason, your BPPS case manager may be able to help you through it. Your case manager can work with you to evaluate your choices. By working closely with you, our goal is to have no disruption in your ongoing treatment.



If you do not have insurance coverage and cannot afford to pay for therapy, we may be able to help

For patients who lack insurance coverage or cannot pay for treatment out of pocket, we can connect you to resources that may be able to provide the assistance you need.

BPPS is here for you

To contact BPPS, call toll free **1-866-906-6100** and press **option #1**.

To obtain more information on NAGLAZYME™ (galsulfase), go to

www.naglazyme.com.



The screenshot shows the Naglazyme website homepage. At the top, the URL www.naglazyme.com is displayed in the browser address bar. The main header features the Naglazyme logo and the text: "The first and only enzyme replacement therapy (ERT) for Maroteaux-Lamy syndrome (MPS VI)". A navigation menu includes "Patients & Families", "Healthcare Professionals", "Contact us", "Naglazyme", and "Clinical trials". A search bar is also present. The main content area is titled "A promising new direction" and includes a testimonial: "We want to thank all patients and families who have taught us about MPS VI...". Below this, there is a section for "Important Safety information" listing adverse events like headache, fever, and arthralgia. A "Billing & Reimbursement" link is visible on the left side.

At BPPS, our priority is to help you begin therapy as promptly as possible.

Indication

NAGLAZYME™ (galsulfase) is indicated for patients with mucopolysaccharidosis VI (MPS VI).

NAGLAZYME has been shown to improve walking and stair-climbing capacity.

Important Safety Information

The most common adverse events observed in clinical trials in patients treated with NAGLAZYME were headache, fever, arthralgia, vomiting, upper respiratory infections, abdominal pain, diarrhea, ear pain, cough, and otitis media. Severe reactions included angioneurotic edema, hypotension, dyspnea, bronchospasm, respiratory distress, apnea, and urticaria. The most common symptoms of infusion reactions included fever, chills/rigors, headache, rash, and mild to moderate urticaria. Nausea, vomiting, elevated blood pressure, retrosternal pain, abdominal pain, malaise, and joint pain were also reported. No patients discontinued for adverse events and all patients who completed the double-blind portion of the trial continued to receive weekly infusions of NAGLAZYME. Nearly all patients developed antibodies as a result of treatment, but the level of immune response did not correlate with the severity of adverse events. Because antihistamine use may increase the risk of apneic episodes, evaluation of airway patency should be considered prior to the initiation of treatment. Consideration to delay infusion of NAGLAZYME should be given when treating patients who present with an acute febrile or respiratory illness.

Please see full Prescribing Information.

Please contact BPPS

Toll free: 1-866-906-6100

E-mail: bpps@BMRN.com

Naglazyme™
(GALSULFASE)

